NEW YORK (360Dx) – DeepMed IO, a Manchester, UK-based company specializing in digital pathology, has received £1 million ($1.3 million) in government funding to support the development and roll out of its platform.

Relying on artificial intelligence, the company has crafted a software tool to assist pathologists in diagnosing cancers and delivering clinical reports. The company plans to introduce its first application for detecting breast cancer metastases on stained lymph-node sections by 2020.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.